Credit Suisse Ag Alnylam Pharmaceuticals, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 129,346 shares of ALNY stock, worth $35.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

129,346

Previous 175,976 26.5%

Holding current value

$35.6 Million

Previous $33.7 Million 42.61%

% of portfolio

0.02%

Previous 0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$146.51 - $198.2 $6.83 Million - $9.24 Million	-46,630 Reduced 26.5%	129,346 $19.3 Million
Q4 2023 Feb 08, 2024	BUY	$151.41 - $196.57 $1.6 Million - $2.08 Million	10,564 Added 6.39%	175,976 $33.7 Million
Q3 2023 Nov 13, 2023	SELL	$170.77 - $211.65 $465,177 - $576,534	-2,724 Reduced 1.62%	165,412 $29.3 Million
Q2 2023 Aug 11, 2023	BUY	$185.01 - $212.05 $6.67 Million - $7.65 Million	36,063 Added 27.31%	168,136 $31.9 Million
Q1 2023 May 10, 2023	BUY	$182.66 - $235.53 $1.09 Million - $1.41 Million	5,994 Added 4.75%	132,073 $26.5 Million
Q4 2022 Feb 13, 2023	BUY	$185.53 - $241.31 $2.33 Million - $3.03 Million	12,570 Added 11.07%	126,079 $30 Million
Q3 2022 Nov 10, 2022	SELL	$138.54 - $232.0 $164,031 - $274,688	-1,184 Reduced 1.03%	113,509 $22.7 Million
Q2 2022 Aug 12, 2022	SELL	$120.42 - $169.29 $592,105 - $832,398	-4,917 Reduced 4.11%	114,693 $16.7 Million
Q1 2022 May 16, 2022	BUY	$127.18 - $173.91 $772,109 - $1.06 Million	6,071 Added 5.35%	119,610 $19.5 Million
Q4 2021 Feb 14, 2022	SELL	$159.56 - $209.29 $7.04 Million - $9.24 Million	-44,147 Reduced 28.0%	113,539 $19.3 Million
Q3 2021 Nov 12, 2021	SELL	$169.75 - $207.73 $4.69 Million - $5.74 Million	-27,625 Reduced 14.91%	157,686 $29.8 Million
Q2 2021 Aug 16, 2021	SELL	$128.63 - $176.89 $5.39 Million - $7.41 Million	-41,886 Reduced 18.44%	185,311 $31.4 Million
Q1 2021 May 14, 2021	BUY	$126.83 - $175.69 $6.72 Million - $9.31 Million	52,963 Added 30.4%	227,197 $32.1 Million
Q4 2020 Feb 12, 2021	BUY	$122.97 - $147.0 $1.58 Million - $1.88 Million	12,820 Added 7.94%	174,234 $22.6 Million
Q3 2020 Nov 13, 2020	SELL	$121.19 - $165.49 $706,295 - $964,475	-5,828 Reduced 3.48%	161,414 $23.5 Million
Q2 2020 Aug 12, 2020	SELL	$104.21 - $156.44 $4.43 Million - $6.66 Million	-42,555 Reduced 20.28%	167,242 $24.8 Million
Q1 2020 May 13, 2020	BUY	$93.12 - $133.99 $3.26 Million - $4.7 Million	35,051 Added 20.06%	209,797 $22.8 Million
Q4 2019 Feb 12, 2020	SELL	$74.51 - $124.23 $1.33 Million - $2.22 Million	-17,896 Reduced 9.29%	174,746 $20.1 Million
Q3 2019 Nov 12, 2019	SELL	$70.9 - $87.82 $7.07 Million - $8.76 Million	-99,736 Reduced 34.11%	192,642 $15.5 Million
Q2 2019 Aug 14, 2019	BUY	$65.86 - $92.79 $661,629 - $932,168	10,046 Added 3.56%	292,378 $21.2 Million
Q1 2019 May 14, 2019	SELL	$72.76 - $93.45 $575,749 - $739,469	-7,913 Reduced 2.73%	282,332 $26.4 Million
Q4 2018 Feb 13, 2019	BUY	$62.67 - $88.33 $2.64 Million - $3.71 Million	42,054 Added 16.94%	290,245 $21.2 Million
Q3 2018 Nov 13, 2018	BUY	$87.52 - $122.67 $3 Million - $4.21 Million	34,302 Added 16.04%	248,191 $21.7 Million
Q2 2018 Aug 14, 2018	SELL	$88.31 - $107.8 $8.71 Million - $10.6 Million	-98,641 Reduced 31.56%	213,889 $21.1 Million
Q1 2018 May 15, 2018	BUY	$115.92 - $148.54 $10 Million - $12.9 Million	86,693 Added 38.39%	312,530 $37.2 Million
Q4 2017 Feb 14, 2018	BUY	$114.49 - $139.98 $7.66 Million - $9.37 Million	66,911 Added 42.1%	225,837 $28.7 Million
Q3 2017 Nov 14, 2017	SELL	$72.53 - $118.27 $1.58 Million - $2.58 Million	-21,817 Reduced 12.07%	158,926 $18.7 Million
Q2 2017 Aug 14, 2017	BUY	N/A	180,743	180,743 $14.4 Million

Others Institutions Holding ALNY

# of Institutions

614

Shares Held

108M

Call Options Held

2.33M

Put Options Held

2.17M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $33.8B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account